Kintara Therapeutics initiates REM-001 15-patient clinical trial

Kintara Therapeutics announced the initiation of a REM-001 15-patient clinical trial in cutaneous metastatic breast cancer patients. This open label 15-patient study in CMBC patients is evaluating REM-001, a second-generation photodynamic therapy photosensitizer agent, and is designed to test the 0.8 mg dose as well as optimize the study design in advance of a Phase 3 trial initiation. The primary endpoint in the study is Best Overall Objective Response Rate of the target treatment fields at any time from treatment up to, and including, week 24.